MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
Sarah Cannon Research Institute
Nashville, Estados UnidosPublicacións en colaboración con investigadores/as de Sarah Cannon Research Institute (6)
2020
-
Phase Ia study of anti-NAPI2B antibody–drug conjugate lifastuzumab vedotin DNIB0600A in patients with non–small cell lung cancer and platinum-resistant ovarian cancer
Clinical Cancer Research, Vol. 26, Núm. 2, pp. 364-372
2018
-
Phase I study of CC-486 alone and in combination with carboplatin or nab-paclitaxel in patients with relapsed or refractory solid tumors
Clinical Cancer Research, Vol. 24, Núm. 17, pp. 4072-4080
2016
-
Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer [Supportive Care in Cancer, (2015), DOI:10.1007/s00520-015-2904-5]
Supportive Care in Cancer
-
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Supportive Care in Cancer, Vol. 24, Núm. 1, pp. 447-455
2013
-
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial
The Lancet Oncology, Vol. 14, Núm. 1, pp. 72-80
2009
-
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
Cancer Chemotherapy and Pharmacology, Vol. 64, Núm. 6, pp. 1139-1148